Author: Daniel snow

Amgen CEO Bob Bradway told CNBC’s Jim Cramer he thinks his company’s obesity drug can help patients manage weight loss long term, which he indicated is a challenge.”We think we can address one of the reasons that the field is struggling a little bit, which is the patient persistence issue,” Bradway said. Amgen revealed Monday that a trial of its experimental GLP-1 drug, MariTide, showed that patients were able to maintain weight loss for two years when given a monthly injection. Right now, most widely-used weight loss injections are taken weekly. Bradway told Cramer that the pharmaceutical giant expects the…

Read More